Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;9(5):1732-1735.
doi: 10.21037/tlcr-20-362.

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined

Christos Chouaïd  1   2 , Nathalie Baize  3 , Isabelle Monnet  1   2
Affiliations
Editorial

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined

Christos Chouaïd et al. Transl Lung Cancer Res. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-362). CC reports grants, personal fees and non-financial support from Roche, Amgen, MSD, BMS, Takeda, Pfizer, Novartis, Health Accord, MundiPharma, Janssen, Bayer, Mylan, outside the submitted work. The other authors have no conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Tsoukalas N, Aravantinou-Fatorou E, Baxevanos P, et al. Advanced small cell lung cancer (SCLC): new challenges and new expectations. Ann Transl Med 2018;6:145-51. 10.21037/atm.2018.03.31 - DOI - PMC - PubMed
    1. Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018;379:2220-9. 10.1056/NEJMoa1809064 - DOI - PubMed
    1. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929-39. 10.1016/S0140-6736(19)32222-6 - DOI - PubMed
    1. Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012;7:866-72. 10.1097/JTO.0b013e31824c7f4b - DOI - PMC - PubMed
    1. Baize N, Monnet I, Greillier L, et al. Second-line treatments of small-cell lung cancers. Expert Rev Anticancer Ther 2017;17:1033-43. 10.1080/14737140.2017.1372198 - DOI - PubMed